Molecular Prognostic Factors in Glioblastoma: State of the Art and Future Challenges

Overview

Journal CNS Oncol

Specialty Oncology

Date 2014 Jul 24

PMID 25054820

Citations 7

Authors

Ana Xavier-Magalhaes

Meera Nandhabalan

Chris Jones

Bruno M Costa

Affiliations

Soon will be listed here.

Abstract

Gliomas account for the majority of primary tumors of the CNS, of which glioblastoma (GBM) is the most common and malignant, and for which survival is very poor. Despite significant inter- and intra-tumor heterogeneity, all patients are treated with a standardized therapeutic approach. While some clinical features of GBM patients have already been established as classic prognostic factors (e.g., patient age at diagnosis and Karnofsky performance status), one of the most important research fields in neuro-oncology today is the identification of novel molecular determinants of patient survival and tumor response to therapy. Here, we aim to review and discuss some of the most relevant and novel prognostic biomarkers in adult and pediatric GBM patients that may aid in stratifying subgroups of GBMs and rationalizing treatment decisions.

Citing Articles

Investigating the relevance of nucleotide metabolism in the prognosis of glioblastoma through bioinformatics models.

Jiang L, Li Z, Ji X, Jiang T, Wang X, Weng C Sci Rep. 2025; 15(1):5363.

PMID: 39948153 PMC: 11825681. DOI: 10.1038/s41598-025-88970-w.

The Potential Use of Radiomics with Pre-Radiation Therapy MR Imaging in Predicting Risk of Pseudoprogression in Glioblastoma Patients.

Baine M, Burr J, Du Q, Liang X, Krajewski L, Zima L J Imaging. 2021; 7(2).

PMID: 34460616 PMC: 8321255. DOI: 10.3390/jimaging7020017.

Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches.

Pirlog R, Susman S, Iuga C, Florian S Medicina (Kaunas). 2019; 55(8).

PMID: 31357616 PMC: 6722920. DOI: 10.3390/medicina55080412.

Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma.

Perdomo-Pantoja A, Mejia-Perez S, Reynoso-Noveron N, Gomez-Flores-Ramos L, Soto-Reyes E, Sanchez-Correa T PLoS One. 2018; 13(11):e0206590.

PMID: 30383794 PMC: 6211735. DOI: 10.1371/journal.pone.0206590.

is a novel oncogenic prognostic biomarker in human glioblastoma.

Goncalves C, Vieira de Castro J, Pojo M, Martins E, Queiros S, Chautard E Theranostics. 2018; 8(17):4805-4823.

PMID: 30279739 PMC: 6160775. DOI: 10.7150/thno.25025.

References

van den Bent M, Dubbink H, Sanson M, van der Lee-Haarloo C, Hegi M, Jeuken J . MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009; 27(35):5881-6. PMC: 2793037. DOI: 10.1200/JCO.2009.24.1034. View

Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A . Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116(6):597-602. DOI: 10.1007/s00401-008-0455-2. View

Backlund L, Nilsson B, Goike H, Schmidt E, Liu L, Ichimura K . Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res. 2003; 9(11):4151-8. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Curran Jr W, Scott C, Horton J, Nelson J, Weinstein A, Fischbach A . Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85(9):704-10. DOI: 10.1093/jnci/85.9.704. View

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent M . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9(5):453-61. DOI: 10.1016/S1470-2045(08)70125-6. View

SUGAWA N, Ekstrand A, James C, Collins V . Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A. 1990; 87(21):8602-6. PMC: 55005. DOI: 10.1073/pnas.87.21.8602. View

Nobusawa S, Stawski R, Kim Y, Nakazato Y, Ohgaki H . Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. Neuropathology. 2011; 31(6):583-8. DOI: 10.1111/j.1440-1789.2011.01204.x. View

Carico C, Nuno M, Mukherjee D, Elramsisy A, Dantis J, Hu J . Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One. 2012; 7(3):e33684. PMC: 3315579. DOI: 10.1371/journal.pone.0033684. View

10.

Cairns R, Mak T . Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013; 3(7):730-41. DOI: 10.1158/2159-8290.CD-13-0083. View

11.

Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y . MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 2010; 1359:14-21. DOI: 10.1016/j.brainres.2010.08.074. View

12.

Tsukada Y, Fang J, Erdjument-Bromage H, Warren M, Borchers C, Tempst P . Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2005; 439(7078):811-6. DOI: 10.1038/nature04433. View

13.

Ahmadloo N, Kani A, Mohammadianpanah M, Nasrolahi H, Omidvari S, Mosalaei A . Treatment outcome and prognostic factors of adult glioblastoma multiforme. J Egypt Natl Canc Inst. 2013; 25(1):21-30. DOI: 10.1016/j.jnci.2012.11.001. View

14.

van Vlodrop I, Niessen H, Derks S, Baldewijns M, Van Criekinge W, Herman J . Analysis of promoter CpG island hypermethylation in cancer: location, location, location!. Clin Cancer Res. 2011; 17(13):4225-31. DOI: 10.1158/1078-0432.CCR-10-3394. View

15.

Hormigo A, Gu B, Karimi S, Riedel E, Panageas K, Edgar M . YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006; 12(19):5698-704. DOI: 10.1158/1078-0432.CCR-06-0181. View

16.

Korkolopoulou P, Levidou G, El-Habr E, Adamopoulos C, Fragkou P, Boviatsis E . Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival. Br J Cancer. 2013; 108(10):2142-52. PMC: 3670505. DOI: 10.1038/bjc.2013.176. View

17.

Iwamoto F, Hottinger A, Karimi S, Riedel E, Dantis J, Jahdi M . Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol. 2011; 13(11):1244-51. PMC: 3199155. DOI: 10.1093/neuonc/nor117. View

18.

Bady P, Sciuscio D, Diserens A, Bloch J, van den Bent M, Marosi C . MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012; 124(4):547-60. PMC: 3444709. DOI: 10.1007/s00401-012-1016-2. View

19.

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

20.

Godlewski J, Nowicki M, Bronisz A, Nuovo G, Palatini J, De Lay M . MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 2010; 37(5):620-32. PMC: 3125113. DOI: 10.1016/j.molcel.2010.02.018. View